Eli Lilly and Company (LLY) Investor presentation summary

Portfolio highlights

• Zepbound is the leading prescribed medicine for obesity, while Mounjaro is the top incretin for type 2 diabetes.

• Foundayo's U.S. obesity launch is ongoing, with global rollout and type 2 diabetes approval expected in 2026/2027.

• Foundayo, Retatrutide, and EloraTZP are positioned to raise the standard of care in cardiometabolic health.

Clinical trial results

• Foundayo demonstrated cardiovascular safety, sustained glycemic control, and weight loss in the ACHIEVE-4 trial, with a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 events compared to insulin glargine.

• Retatrutide achieved up to 20.8% weight loss at 80 weeks in patients with obesity and type 2 diabetes in the TRIUMPH-2 study.

• EloraTZP delivered up to 23% weight loss at 48 weeks in a Phase 2 study, with the high-dose combination outperforming monotherapies.

Safety and tolerability

• Retatrutide's most common adverse events were gastrointestinal, with most being mild to moderate and resolving during treatment.

• Eloralintide showed favorable GI tolerability, and EloraTZP's adverse event profile was consistent with other incretin therapies.